https://hsci.harvard.edu/news/new-therapy-treating-type-1-diabetes
A new therapy for treating Type 1 diabetes
VX-880
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-day-90-data-first-patient-phase-12
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04786262?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=02%2F22%2F2021&lupd_d=14&sort=nwst
STUDY TITLE:
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
DESCRIPTION:
Conditions: Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe Hypoglycemia
Intervention: Biological: VX-880
Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT04786262
FIRST POSTED:
Mon, 08 Mar 2021 12:00:00 EST
LAST UPDATE POSTED:
03/08/21 06:09AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04786262?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=02%2F22%2F2021&lupd_d=14&sort=nwst
